Correct administration and usage recommendations of Entrectinib

Entrectinib is an oral small molecule targeted drug, mainly suitable for patients with advanced solid tumors or non-small cell lung cancer (NSCLC) with NTRK fusion or ROS1 rearrangement. As one of the representative drugs of precision medicine, entrectinib inhibits tumor growth by targeting tumor driver gene fusion. In order to ensure the effectiveness of the drug and reduce side effects, patients should strictly follow their doctor's instructions when taking this drug. The following will introduce in detail the taking methods, medication suggestions, precautions and combined treatments.

1. Recommended dosage and administration method

Entrectinib should be used under the guidance of a doctor. The standard recommended dose is 600mg once a day for adults (i.e. 200mgcapsules3 capsules), administered orally. In pediatric patients, adjust dose based on body surface area (BSA). Entrectinib should be swallowed whole and should not be broken, chewed or dissolved. It is not recommended to change the dosage form in other ways to avoid affecting drug release and absorption.

The drug can be taken on an empty stomach or after meals and has no obvious dependence on food. However, in order to reduce possible gastrointestinal irritation, it is recommended that patients take it after meals, especially during the initial use. The medication time should be kept fixed to help maintain stable blood concentration and therapeutic effect.

2. Medication duration and course adjustment

There is no fixed treatment limit for the period of use of entrectinib. It is generally recommended to continue taking it when the disease is stable or there is no disease progression. During treatment, patients should regularly undergo imaging examinations such as CT or MRI to monitor whether the tumor has shrunk, stabilized or progressed, and if necessary, decide whether to continue treatment based on efficacy and side effects.

If a patient experiences drug-related adverse reactions, the doctor may recommend temporarily discontinuing the drug, reducing the dose, or adjusting the frequency of dosing. Recommended dose adjustment standards for entrectinib include: reducing from 600 mg to 400 mg and then to 200 mg. If the patient is unable to tolerate 200 mg, permanent discontinuation is usually recommended.

3. Combined medication and drug interactions

Other drugs should be used with caution while taking entrectinib, especially drugs that may affect the metabolism of entrectinib. Entrectinib is mainly metabolized by CYP3A enzyme and is highly potent CYP3A4Inhibitors (such as ketoconazole, itraconazole) or inducers (such as rifampicin) may change their concentration in the body, thereby affecting efficacy or increasing toxicity. Therefore, if you need to combine other drugs, you should consult your doctor or pharmacist in advance.

In addition, entrectinib may affect QT interval prolongation or the central nervous system, so special caution should be used when combined with drugs with the same risk of effects, especially patients with heart disease, hypertension or brain metastases should be closely monitored.

4. Adverse reaction management and medication recommendations

Common adverse reactions include: fatigue, taste changes, constipation, dizziness, increased liver function indicators, anemia, edema, etc. Some patients may also experience neurological symptoms such as movement coordination disorders or confusion. If symptoms are severe, you should report to your doctor promptly to evaluate whether the medication needs to be discontinued or the dosage adjusted.

Patients should regularly check liver function, blood routine, electrolytes and electrocardiogram while taking the drug, especially during the initial treatment and dose adjustment stage. Patients with brain metastases should pay attention to central nervous system side effects when taking entrectinib, and regularly evaluate neurological function and mental status.

At the same time, you should avoid drinking grapefruit juice or eating grapefruit products during entrectinib treatment, because these will inhibit theCYP3A enzyme, which may lead to an increase in blood concentration and increase the risk of adverse reactions.

5. Suggestions for use by special groups of people

Children and Adolescents: Entrectinib is suitable for children 12 years old and above. However, the dose should be adjusted according to the body surface area and must be used under the guidance of an experienced oncologist.

Pregnant and lactating women: There is currently insufficient clinical data to confirm the safety of entrectinib for pregnant women or fetuses, so it is contraindicated during pregnancy. If lactating patients need to take medication, lactation should be discontinued.

Elderly people: Clinical trials have not shown significant differences in efficacy between the elderly and young people, but because elderly patients have more comorbidities, drug response needs to be monitored more frequently.

Patients with abnormal liver and kidney function: Patients with mild liver dysfunction do not need to adjust the dose, but patients with moderate to severe liver function should use it with caution and closely monitor pharmacokinetics and adverse reactions.

6. Suggestions for daily management of patients

During entrectinib treatment, patients should establish good medication habits, take medication at a fixed time every day, and do not change the dosage at will. If symptoms of discomfort occur, they should be proactively recorded and reported to the doctor in a timely manner. During treatment, it is recommended to eat regularly, maintain adequate fluid intake, avoid fatigue, and avoid infection as much as possible.

In addition, patients should maintain a positive attitude, maintain good communication with doctors and pharmacists, and follow regular follow-up arrangements. Some patients may purchase the drug overseas or use generic drugs. They should pay special attention to the legality and quality of the drug source and avoid using fake drugs or low-quality products.

Entrectinib is an anti-cancer drug with precise efficacy and precise targeting, and is suitable for patients with solid tumors or lung cancer with specific gene fusions. It is taken orally once a day, and the dosage must strictly follow the doctor's instructions. During the treatment process, drug efficacy and side effects need to be closely monitored to prevent drug interactions and ensure patient safety. Long-term persistence and scientific use of medication will help maximize the therapeutic benefits of entrectinib.

Reference: https://go.drugbank.com/drugs/